Effects of TRPM8 on the proliferation and angiogenesis of prostate cancer PC-3 cells in vivo

Zhu,Guangbin; Wang,Xinghuan; Yang,Zhonghua; Cao,Hong; Meng,Zhe; Wang,Yongzhi; Chen,Dong

doi:10.3892/ol.2011.410

Effects of TRPM8 on the proliferation and angiogenesis of prostate cancer PC-3 cells in vivo

Authors:
- Guangbin Zhu
- Xinghuan Wang
- Zhonghua Yang
- Hong Cao
- Zhe Meng
- Yongzhi Wang
- Dong Chen
View Affiliations

Affiliations: Department of Urology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: September 2, 2011 https://doi.org/10.3892/ol.2011.410
Pages: 1213-1217

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer is a significant health concern. In the early stages, prostate cancer cells depend on androgens for growth and survival, hence androgen-ablation therapy at this time may be effective in causing tumor regression. However, treatment options for advanced hormone-refractory prostate cancers are still relatively inefﬁcient. This study aimed to investigate the possible effects of TRPM8 on the proliferation and angiogenesis of androgen-independent cancer PC-3 cells in vivo. Thirty male nude mice were divided into three groups: the PC-3, PC-3-vector and PC-3-TRPM8 groups. PC-3, PC-3-vector and PC-3-TRPM8 cells were respectively inoculated in the right flank to establish a transplanted tumor model. The mice were treated daily for four weeks and each group was examined by histology and immunohistochemical staining for CD34, FAK and PCNA. A CD34 marked microvascular density (MVD) test was performed. Western blot analysis was used to detect the VEGF protein expression level. Compared to the PC-3 and PC-3-vector groups, the PC-3-TRPM8 group revealed a decrease in tumor volume (P=0.000 and P=0.000, respectively), MVD (P=0.045 and P=0.041, respectively), VEGF (P=0.000 and P=0.000, respectively), FAK and PCNA. The correlation between MVD and VEGF was positive (r=0.419; P=0.021). These data show that the overexpression of TRPM8 had a negative effect on the proliferation and angiogenesis progression of PC-3 cells in vivo.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
2	Martel CL, Gumerlock PH, Meyers FJ and Lara PN: Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev. 29:171–187. 2003. View Article : Google Scholar : PubMed/NCBI
3	Berridge MJ, Lipp P and Bootman MD: The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol. 1:11–21. 2000. View Article : Google Scholar : PubMed/NCBI
4	Tsavaler L, Shapero MH, Morkowski S and Laus R: Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 61:3760–3769. 2001.
5	Henshall SM, Afar DE, Hiller J, et al: Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 63:4196–4203. 2003.PubMed/NCBI
6	Zhang L and Barritt GJ: Evidence that TRPM8 is an androgen-dependent Ca²⁺ channel required for the survival of prostate cancer cells. Cancer Res. 64:8365–8373. 2004. View Article : Google Scholar : PubMed/NCBI
7	Yang ZH, Wang XH, Wang HP and Hu LQ: Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells. Asian J Androl. 11:157–165. 2009. View Article : Google Scholar : PubMed/NCBI
8	Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
9	Brawer MK, Deering RE, Brown M, Preston SD and Bigler SA: Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer. 73:678–687. 1994. View Article : Google Scholar : PubMed/NCBI
10	Ferrer FA, Miller LJ, Andrawis RI, et al: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol. 157:2329–2333. 1997. View Article : Google Scholar : PubMed/NCBI
11	Jackson MW, Bentel JM and Tilley WD: Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol. 157:2323–2328. 1997. View Article : Google Scholar : PubMed/NCBI
12	Borre M, Nerstrom B and Overgaard J: Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res. 6:1882–1890. 2000.
13	Warri AM, Huovinen RL, Laine AM, Martikainen PM and Harkonen PL: Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst. 85:1412–1418. 1993. View Article : Google Scholar : PubMed/NCBI
14	Parsons JT, Slack-Davis J, Tilghman R and Roberts WG: Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res. 14:627–632. 2008. View Article : Google Scholar : PubMed/NCBI
15	Chang YM, Kung HJ and Evans CP: Nonreceptor tyrosine kinases in prostate cancer. Neoplasia. 9:90–100. 2007. View Article : Google Scholar : PubMed/NCBI
16	Voets T, Owsianik G and Nilius B: Trpm8. Handb Exp Pharmacol. 329–344. 2007. View Article : Google Scholar
17	Gkika D, Flourakis M, Lemonnier L and Prevarskaya N: PSA reduces prostate cancer cell motility by stimulating TRPM8 activity and plasma membrane expression. Oncogene. 29:4611–4616. 2010. View Article : Google Scholar : PubMed/NCBI
18	Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 64:327–336. 1991. View Article : Google Scholar : PubMed/NCBI
19	Ferrer FA, Miller LJ, Lindquist R, et al: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 54:567–572. 1999. View Article : Google Scholar : PubMed/NCBI
20	Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A and Biagini G: Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate. 45:72–79. 2000. View Article : Google Scholar
21	Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML and Merino MJ: Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 147:33–41. 1995.PubMed/NCBI
22	Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 143:401–409. 1993.PubMed/NCBI
23	Kosaka T, Miyajima A, Takayama E, et al: Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate. 67:41–49. 2007. View Article : Google Scholar : PubMed/NCBI
24	Tanaka S, Haruma K, Tatsuta S, et al: Proliferating cell nuclear antigen expression correlates with the metastatic potential of submucosal invasive colorectal carcinoma. Oncology. 52:134–139. 1995. View Article : Google Scholar
25	Lacoste J, Aprikian AG and Chevalier S: Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility. Mol Cell Endocrinol. 235:51–61. 2005. View Article : Google Scholar : PubMed/NCBI
26	Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE and Parsons JT: Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene. 20:1152–1163. 2001. View Article : Google Scholar : PubMed/NCBI